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Abstract. Injuries to the central nervous system continue to be vast contributors to
morbidity and mortality; speciﬁcally, traumatic brain injury (TBI) is the most common cause
of death during the ﬁrst four decades of life. Several modalities are used to monitor patients
suffering from TBI in order to prevent detrimental secondary injuries. The microdialysis
(MD) technique, introduced during the 1990s, presents the treating physician with a robust
monitoring tool for brain chemistry in addition to conventional intracranial pressure
monitoring. Nevertheless, some limitations remain, such as limited spatial resolution.
Moreover, while there have been several attempts to develop new potential pharmacological
therapies in TBI, there are currently no available drugs which have shown clinical efﬁcacy
that targets the underlying pathophysiology, despite various trials investigating a plethora of
pharmaceuticals. Speciﬁcally in the brain, MD is able to demonstrate penetration of the drug
through the blood-brain barrier into the brain extracellular space at potential site of action.
In addition, the downstream effects of drug action can be monitored directly. In the future,
clinical MD, together with other monitoring modalities, can identify speciﬁc pathological
substrates which require tailored treatment strategies for patients suffering from TBI.
KEY WORDS: drug delivery; human; microdialysis; monitoring; pharmacokinetics; traumatic brain
injury.
INTRODUCTION
Central nervous system (CNS) injuries, including condi-
tions such as stroke, subarachnoid haemorrhage and trau-
matic brain injury, are great contributors of morbidity and
mortality (1–3). As well as the primary injury or haemorrhage
additional secondary injuries lead to deterioration with
neuroinﬂammation, neurotoxicity and deranged metabolism
causing further tissue swelling, distress and cellular death (4).
While this underlying pathophysiology may overlap for
different CNS conditions, there are no approved pharmaco-
logical treatments that have shown adequate efﬁcacy in
targeting these conditions. Speciﬁcally in traumatic brain
injury (TBI), physicians are left with the options of decom-
pressive surgery (5), intravenous hyperosmolar therapy (6),
sedative agents (7), hypothermia (8), hyperventilation (9) and
anti-epileptic drugs (10) in order to treat the subsequent
effects of affected tissue deterioration. The secondary insults
which emerge as a result of these pathological derangements,
including among others increased intracranial pressure (ICP)
and decreased cerebral perfusion pressure (CPP), are closely
monitored in the neuro-critical care unit (NCCU) as such
derangements have been shown to lead to unfavourable
outcome (11). Currently, ICP-targeted therapy is commonly
used worldwide, as suggested by the updated Brain Trauma
Foundation guidelines (12). However, ICP-targeted therapy
has not been shown to improve outcome versus patients not
monitored with ICP in a randomized control trial (13). That
trial (BEST-TRIP) by Chesnut et al. concluded that care
focused on maintaining ICP at 20 mmHg or less was not
superior to care based on imaging and clinical examination.
However, patients in both arms received tiered ICP-lowering
therapies, and a decompressive craniectomy was performed
in 30% of patients in each arm. Hence, the BEST-TRIP trial
ﬁndings (13) do not challenge the belief that brain oedema
and raised ICP should be actively managed after TBI (14).
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One likely reason that ICP monitoring in isolation does not
improve outcome is that there are a number of paths to
neuronal injury and it is only by considering the full scope of
metabolic derangements that secondary injuries to the brain
can be avoided and clinical outcome improved (15). Here,
microdialysis (MD) is playing an important role in many
NCCUs today for patients suffering from TBI and subarach-
noid haemorrhage (SAH) (16), but is also actively researched
in other CNS conditions such as bacterial meningitis (17, 18)
and spinal cord injury (19).
Few pharmaceutical compounds diffuse freely from
blood over the blood-brain barrier (BBB) into the brain
parenchyma (20). While the blood-cerebrospinal ﬂuid (CSF)
barrier is more permissive, the brain-CSF barrier and BBB
are a distinct and potent obstacle (at the cellular and
molecular levels) for potential neurological drug candidates
(21, 22). While the BBB provides important physiological
beneﬁts by excluding neuroactive substances, both endoge-
nous and exogenous, from entering the brain, it creates an
impediment for pharmacological development. This inherent
barrier could explain why only 8% of drug candidates
targeting CNS conditions become clinically available treat-
ments, as compared to 15% overall (23). Thus, measuring
drug concentrations in CSF is not representative of drug
action; as even if it provides an estimate of CNS penetration,
signiﬁcant concentration gradients between the brain paren-
chyma (extracellular ﬂuid, ECF) and CSF have been empir-
ically demonstrated (24). To gain access to brain ECF for
pharmacokinetic monitoring, the only currently available
option is microdialysis (MD) (25, 26). Table I summarizes
the beneﬁcial effects of MD monitoring in pharmacological
trials in TBI, as has been previously reviewed in the literature
(27). Moreover, new clinical ﬁndings suggest that the MD
technique could open up new routes of focal drug adminis-
tration (28), bypassing innate barriers, although more re-
search is necessary to fully validate the technique.
In summary, the microdialysis technique enables the
clinician to monitor the metabolic state of the brain, to
map pharmacokinetic concentration gradients of delivered
drugs in the brain parenchyma as well as a potential route
of drug administration focally, bypassing the BBB. The
aims of this review are to elaborate on these aspects of
MD monitoring and to provide the reader with the
history, present application and future directions of
clinical microdialysis in human TBI.
THE MICRODIALYSIS AS A CLINICAL MONITORING
TOOL IN TRAUMATIC BRAIN INJURY
The History of Clinically Applied Microdialysis
Microdialysis (MD) was developed by Urban Ungerstedt
at the Karolinska Institutet, Sweden, in the 1970s. MD was
ﬁrst described in 1974 (29), where the authors used a hollow
dialysis ﬁbre attached to a steel cannula implanted in rat brain
to extract dopamine. While the device was novel, the concept
of push-pull extraction, similar to MD, was ﬁrst described in
the early 1960s (30). The ﬁrst MD devices were implanted
horizontally through the brain (31), although Ungerstedt and
co-workers later developed the ﬁrst vertical probe containing
both delivery and return cannulae arranged concentrically in
the same housing in the 1980s (32). The MD catheters used
then resemble the devices used today, consisting of a semi-
permeable membrane which is inserted into the organ of
interest through which a carrier ﬂuid is slowly pumped.
Substances will move from the extracellular ﬂuid (ECF),
through the pores of the membrane, into the carrier ﬂuid, by
diffusion, which is subsequently pumped out of the return
catheter and is available for analysis. The ﬁrst brain MD
catheter implantation in humans was performed at the
Karolinska University Hospital, Sweden, in 1990, where it
was stereotactically inserted in patients with Parkinson’s
disease in order to study mono-amine concentrations in the
basal ganglia (33). In the same year, researchers from
Uppsala University, Sweden, monitored a patient undergoing
tumour resection with MD and found brain lactate levels
similar to what was seen in preclinical models of ischemia
(34), thus suggesting brain extracellular ﬂuid lactate to be a
valid surrogate marker for cerebral metabolic disturbances.
In 1992, the same group presented how they successfully
integrated MD at the bedside in the neuro-critical care unit
(NCCU) (35), thus providing the treating physician with the
metabolic state of the cerebral extracellular environment. In
1995 and 2002, the MD technique became approved by
regulating authorities for widespread clinical use in Europe
and USA, respectively. During the latter part of the 1990s, the
technology became more readily available for hospitals
worldwide due to advancements in computing hardware
(36). Since then, the technique has been extensively reﬁned,
and a multitude of methodological variants have been
introduced to improve monitoring of the injured brain.
Microdialysis Monitoring of the Injured Brain
Through several consensus meetings, practising clinicians
have contributed recommendations and expert opinion on
how to best use, interpret and assess MD and MD ﬁndings
(16, 37, 38). Clinically, the metabolites glucose, lactate,
pyruvate, glycerol and glutamate are sampled at the bedside.
The latest consensus meeting, 2014, identiﬁed the most
important metabolites to measure based on the weight of
evidence in the published literature, as surrogate markers of
substrate delivery failure and the oxygenation state of the
brain, namely glucose, lactate, pyruvate and the lactate/
pyruvate ratio (LPR) (16). A brain ECF glucose <0.2 and a
LPR >25 in TBI have both been suggested as thresholds as
they have been found to correlate to an unfavourable long-
Table I. Advantages with MD Use in Pharmaceutical Trials
Advantages of MD monitoring in drug studies
Pharmacokinetics of drug concentration in brain ECF
Efﬁcacy of bound/unbound drug concentration
Dose-response effects in vivo
Limit the effects of intra-patient heterogeneity by direct measure-
ment of concentrations achieved
Analyse surrogate markers of drug efﬁcacy in microdialysate
A list of beneﬁts of MD monitoring in pharmacological trials of
neuroprotective drugs
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term outcome for patients (39, 40). A simpliﬁed schematic of
major energy pathways in the brain is shown in Fig. 1.
Through glycolysis, glucose will generate pyruvate. Further-
more, if there is an impairment in oxidative phosphorylation
within the mitochondrion, either due to oxygen limitation or
to mitochondrial dysfunction (41, 42), this will lead to an
accumulation of lactate, and increased LPR in brain ECF.
Lactate dehydrogenase (LDH) catalyses the biochemical
conversion between lactate and pyruvate. Furthermore, the
dynamic balance between lactate and pyruvate is determined
by the cellular concentration of reducing equivalents
(NADPH/NADH) that drive the ﬂux towards lactate. In this
way, LPR is a direct measure of the cellular redox state and is
the single most biochemically useful metric for use as part of
multi-modal monitoring in NCCUs.
The LPR is generally regarded as a more useful clinical
marker than lactate concentration alone, although both
lactate and pyruvate, along with glucose, also need to be
reported individually for proper interpretation of bedside
microdialysate monitoring as mentioned above, while gluta-
mate and glycerol are considered of lesser priority (16).
Lactate can be metabolised via the TCA cycle, and the
astrocyte-neuron lactate shuttle hypothesis has been pro-
posed whereby lactate produced by astrocyte glycolysis can
be used as a fuel by neurons (43). This hypothesis has been
subject to much debate and discussion over time. For a recent
review on glycolysis and the signiﬁcance of lactate in TBI, see
(44). Interestingly, lactate can also spin out of the TCA cycle,
a process termed cataplerosis (45). While this has previously
been noted in experimental studies, our novel discovery of
the TCA cycle as a source of lactate in human TBI brain calls
for revision of lactate’s signiﬁcance, hitherto regarded as
simply glycolytic, with possible implications for other diseases
too (28).
Challenges in Clinical MD Metabolic Monitoring
There are several inherent limitations to the MD
technique, such as relative recovery (deﬁned as the ratio of
the concentration that is in the extracted dialysate to a true
concentration of a given substance) (46) and the limited
temporal resolution (by convention, 1 h per sample even if
more frequent monitoring is possible), which have been
previously reviewed (22, 47). In the following discussion, we
have chosen to focus on speciﬁc aspects of clinical microdi-
alysis which might cause difﬁculties in MD assessment and
utilization.
The focal nature of microdialysis monitoring has been
suggested as the key reason why the technique is struggling to
gain ground in the ﬁeld (48). As shown by several groups,
catheters placed in ‘peri-contusional’ tissue have higher LPR
compared to catheters placed in unaffected tissue, as deﬁned
by head computerized tomography (39, 49, 50). This is further
supported by Nelson et al. which noticed differences in MD
parameters between catheters placed two centimetres away
from mass lesions, compared to catheters placed in closer
proximity (51). The criticism is that it is difﬁcult to extrapo-
late 1 cm3 of MD-monitored brain tissue to the metabolic
state of the whole brain. In order to overcome this issue, Stein
and co-workers have proposed a ‘global metabolic crisis’
(LPR > 25 with simultaneous brain ECF glucose levels <0.8
mmol/L) if radiologically normal-appearing brain not close to
focal lesions brain tissue is monitored (52), which was also
shown to be independently correlated with long-term out-
come. This is usually the most practicable option for MD
catheter placement, as speciﬁcally directing the microdialysis
catheter close to lesions is technically demanding and
sometimes impossible. Another way to increase the spatial
resolution is to monitor blood outﬂow from the brain using
microdialysis placed in jugular venous efﬂux, where a higher
LPR has been seen following experimental haemorrhagic
shock (53). Alternatively by monitoring the CSF compart-
ment, a more global measure of brain metabolism can be
derived. By a modiﬁed set-up, consisting of a microdialysis
catheter inserted into the ventricular CSF via an external
ventricular drain, this has been performed and provides
higher temporal resolution sampling of CSF metabolites by
using the MD technique rather than intermittent CSF
sampling (54). The converse argument is that by monitoring
a larger compartment, the sensitivity of the technique is
reduced as focal areas of metabolic crisis may be masked by
dilution of the signal from areas of the brain that have a less
severe injury. These arguments between focal and global
monitors have been well rehearsed in the literature in relation
to oxygenation parameters and jugular venous oximetry vs
focal brain tissue oxygen monitors. In reality, there is no
conﬂict in combining both focal and global monitoring
techniques to enhance our understanding of the underlying
pathophysiology as both approaches have their relative
merits. Microdialysis, as a continuous extracellular monitor-
ing technique, can complement evidence from scans such as
positron emission tomography (PET) and magnetic
Fig. 1. Simpliﬁed schematic of major energy pathways in the brain
includes glycolysis, which takes places in the cytosol and produces
pyruvate, which enters mitochondria and is converted into acetyl
CoA that enters the TCA cycle. Alternatively, pyruvate can stay in
the cytosol and is converted into lactate that is exported out of the
cell. The pentose phosphate pathway (PPP) takes place in the cytosol
and is an alternative energy pathway that can be upregulated after
injury; it is an important source of NADPH used to produce the
reduced form of glutathione (GSH) for preventing oxidative stress.
This ﬁgure was originally published by Carpenter et al. in Eur J
Pharm Sci 57 (2014) 87–97. © 2014 The Authors. Published by
Elsevier B.V. Open Access under a CC–BY licence
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resonance imaging (MRI) or magnetic resonance spectros-
copy (MRS) that provide global ‘snap-shots’ of the brain
tissue that predominantly reﬂect the intracellular environ-
ment (14).
However, there is evidence that following brain injury,
the global metabolic state of the injured brain is altered, for
example using PET monitoring of the utilization of glucose
(55–57), revealing different metabolic derangements. These
studies also show on the potential of MD as a focal but
dynamic monitor while PET provides a cross-sectional whole
brain snapshot and the combination of the two provides
complementary data. Moreover, PET can also be used to
provide focal data, as regions of interest can be evaluated as
desired, during data processing. For example, studies by
Hutchinson et al. evaluated oxygen metabolism and cerebral
metabolic rate of glucose (CMRglc) in regions of interest
(ROIs) drawn around the MD catheter tips in triple-oxygen
and labelled 2-ﬂuoro-2-deoxy-D-glucose (FDG)-PET scans,
respectively (58, 59). In a study by Timofeev and co-workers,
up to 75% of the catheters were in radiologically (CT)
‘uninjured’ tissue; nevertheless, the LPR threshold of >25
correlated with clinical outcome (39). Moreover, different
types of intracranial lesions impact on LPR to a greater
degree, such as subdural hematomas and contusions (as high
as a factor 10x) as compared to epidural hematomas and
diffuse injuries (60). This reﬂects a difference in the metabolic
sequelae of these patterns of TBI that is detected by MD
monitoring and may carry additional prognostic information
and guide therapy.
The MD technique in clinical use has shown high auto-
correlation within the same patient (51, 61). This make data
trends as important as speciﬁc levels for the individual
patient, stressing the need for good threshold levels in order
to generalize the technique. In small studies, a useful
approach is for each TBI patient to be used as his or her
own control (28). Notably, TBI microdialysis data have been
found to be highly auto-correlated even with samples at up to
30 h later, and subject identity alone explains 52 to 75% of
microdialysis marker variance, determined in a large study
(over 7350 hourly samples of complete microdialysis sets from
90 TBI patients) using statistical and pattern-recognition
computer models (51). Thus, since microdialysate data are
highly individualized, it is therefore logical to use each patient
as his/her own control and examine temporal trends rather
than comparing with a separate control group of separate TBI
patients.
Another suggested limitation is the potential damage
created by the insertion of the microdialysis catheter into
brain parenchyma. While this has been shown in preclinical
models (62), it is difﬁcult to assess the extent of injury in the
clinical monitoring in a disease such as severe TBI, and no
studies have reported on any traumatic complications due to
catheter insertion. However, it is recommended that the ﬁrst
2 hours of MD sampling collected should not be used to guide
care as these may represent unreliable results caused by the
insertion and the pump-ﬂush sequence (16).
While the frequency of haemorrhagic and infectious
complications in patients with multimodality monitoring is
low (63), the amount of MD catheters that either become
dysfunctional for unknown reasons or that are unintentionally
removed due to the everyday care is fairly high (>10% in
selected studies) (64, 65). The care provided in the NCCU
requires patient turning, hoisting and transfer to neuroimag-
ing, which may all result in unintentional MD catheter
removal. A way to minimize the risk is to attach the catheter
through a bolt where other devices, such as brain oxygen
pressure and intracranial pressure probes, can also be
inserted (66).
In aggregate, the MD technique presents both theoret-
ical and practical limitations. However, steps can be taken in
order to minimize these caveats in clinical practice.
Microdialysis to Monitor Drug Pharmacokinetics in the CNS
In the ﬁeld of TBI, there are numerous substances that
have shown neuroprotective effects in vitro as well as
promising efﬁcacy in vivo in small animal models. However,
the transition to the clinic has proven difﬁcult, and large,
multicentre trials studying corticosteroid (67), erythropoietin
(68) and progesterone (69), all showing promising preclinical
efﬁcacy, have failed to show adequate treatment efﬁcacy in
human TBI. One of the reasons why drug development in
brain injury has been challenging is the heterogeneous nature
of the disease, making it impossible to treat all TBI patients
using a single ‘golden bullet’. Another limitation is that none
of these previously mentioned trials have measured the drug
concentration in brain ECF (or CSF for that matter); thus,
they go straight from preclinical efﬁcacy in animal models to
clinical outcome in patients and thereby overlook the putative
desired pathophysiological effects these drugs might have in
the patients, or if there is a dose-response correlation for
unbound drug in the CNS (27, 70). Moreover, without
measuring brain ECF concentrations of drugs, these studies
have not established whether the drug has reached its target
compartment. Inadequate pharmaceutical monitoring of
brain ECF was also evident in the recent operation brain
trauma therapy (OBTT) where a consortium of laboratories
tested a number of different substances in rodent models of
brain injury (71). While few drugs showed promising results
(the best effect was shown by the anticonvulsant levetirace-
tam (72)), the authors did not measure CSF or brain ECF
concentrations, thus limiting the understanding of dose-
response, as well as if an adequate amount of drug even
reached the CNS. Sufﬁce to say, there is a need for better
pharmacokinetic monitoring when developing studies
analysing drug transportation in brain injury trials. In order
to establish that a drug has reached the site of pharmacolog-
ical action in the CNS, there are strong theoretical reasons to
favour the brain ECF compartment where the MD technique
is currently the only option in human patients.
This is further highlighted in studies analysing antibi-
otic concentrations (meropenem and doripenem) in the
brain ECF compartment following TBI (73, 74). In patients
with TBI, bacterial meningitis and other cerebral infectious
complications occur in up to 17.2% of TBI patients (75, 76),
and the risk increases the longer the period of external
ventricular drain monitoring is (77). However, in the more
general sense, TBI can provide a model for testing the
penetration of these antibiotics into the brain ECF to
inform dosing in other pathologies. These studies stress
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the need to monitor the brain ECF compartment as it shows
much lower antibiotic concentrations compared to serum,
even if the extraction fraction (relative recovery) is taken
into account, and to what has comparably been detected
previously in the CSF (78). Microdialysis can thus provide
important evidence as to whether the antibiotic minimum
inhibitory concentration (MIC) can be attained in the brain.
Treatment of cerebral infections is still a challenge, and that
some of the dosages of antibacterial drugs may be inade-
quate for more resistant bacteria despite seemingly ‘effec-
tive’ plasma concentrations (79). Cerebral microdialysis
pharmacokinetics studies of antibiotics can thus form the
basis of more accurate dosage for patients with CNS
infections (79).
Another pharmacokinetic study employing microdialy-
sis in TBI patients has focused on vigabatrin (VGB), an
anticonvulsant and putative neuroprotectant (80, 81). VGB,
given enterally to severe TBI patients, crossed the BBB into
the brain ECF, where it accumulated with multiple dosing.
Pharmacokinetics suggest delayed uptake from the blood.
Microdialysate VGB concentrations were higher close to
focal lesions, possibly as a consequence of locally greater
BBB permeabi l i ty, than those in dis tant s i tes .
Microdialysate GABA concentrations increased modestly
in some of the patients after VGB administration, consistent
with the mode of action of VGB as an inhibitor of GABA-
transaminase, an enzyme responsible for degrading GABA.
Analogous to the situation with antibiotics (above), micro-
dialysis has a potential role to inform on dosing of
anticonvulsants and neuroprotectants. For example, the
causes of refractory epilepsy (occurrence of seizures despite
anticonvulsant drug treatment) are not known, but inade-
quate drug concentration in crucial brain areas is a possible
contributing factor. Knowledge about more appropriate
dosing may thus ensue from microdialysis pharmacokinetic
measurements.
Clinical microdialysis studies with small numbers of
patients may be sufﬁcient to show whether particular drug
candidates might be worth pursuing further in larger clinical
trials. A microdialysis study by Hutchinson et al. (82)
investigated the potentially neuroprotective drug
chlormethiazole in ﬁve TBI patients. This drug proved to be
undetectable in brain microdialysates, suggesting that it did
not reach the target site to exert its action. Interestingly, in a
phase III clinical trial, chlormethiazole did not improve the
outcome in patients with major ischemic stroke (83). This
expensive, time-consuming and unsuccessful phase III trial
could potentially have been avoided by ﬁrst carrying out an
in vivo clinical microdialysis study.
THE FUTURE OF CLINICAL MICRODIALYSIS IN
TRAUMATIC BRAIN INJURY
Clinical Utility of the Lactate/Pyruvate Ratio
We acknowledge that monitoring of the biochemical
state of the injured brain is complex, and that more research
is necessary in order to fully understand intricate relation-
ships between brain metabolites and proteins. Hence, we
believe that there is a direction to facilitate monitoring using
solely the LPR to monitor patients. While the LPR in theory
is a robust tool, we believe it is best together with other
parameters.
Today, there are several different treatment strategies for
a range of different intracranial conditions. Moreover, several
monitoring modalities make it possible for the treating
clinician to gain a better understanding of the ongoing
pathological substrates in the injured brain. Different ‘path-
ophysiological targets’ have been suggested (15, 60, 84),
including distinctive deﬁnitions of ‘ischemia’, ‘hypoperfusion’
and ‘mitochondrial dysfunction’.
We suggest, based on the discussions and data presented
during the latest consensus meeting (16), that LPR could act
as guide as it would indicate deranged energy generation at
the cellular level, creating a more informative monitor as
compared to ICP, and that LPR could be used to further
direct therapy based on other monitored modalities. Thus, we
propose the following pathophysiological targets if the LPR is
increased (>25) (Table II):
– If the LPR increase is concomitant with an
increased ICP (>20 mmHg), the patient could be suffering
from ‘intracranial hypertension’.
– If the ICP is normalized, but LPR is increased
and the brain pressure oxygen is simultaneously affected
(<15 mmHg). This may be due to ‘delivery failure’ of oxygen
if the cerebral perfusion pressure (CPP) is decreased and
outside the auto-regulatory range (pressure reactivity index
(PRx) >0.3) (85) or a ‘diffusion barrier’ if the CPP is adequate
(86).
– If both normal ICP and substrate delivery
through adequate perfusion and oxygen pressures have been
established, but the LPR increase remains and brain ECF
glucose is low (<0.5–1.0 mmol/L), it could indicate low
glucose in the affected brain tissue (87) (also referred to as
‘neuroglycopenia’). This could both be due to an increased
diffusion path for glucose or downregulation of glucose
transporters (88).
– If both oxygen and glucose delivery are ade-
quate, together with a normal ICP, but the deranged LPR
persists, this would fall under the deﬁnition of ‘mitochondrial
dysfunction’ (42), i.e. an inability of the brain tissue to meet
energy demands despite adequate substrate and oxygen
delivery.
Another pathophysiological state worth mentioning is
hyperglycolysis (55, 56), where the utilization of glucose in
the tissue increases, as visible by PET imaging, with a
simultaneous increase in brain ECF lactate and pyruvate
levels (59). The underlying pathophysiology is unknown and
could be due to focal seizure activity, spreading
depolarisation, and/or mitochondrial dysfunction. Subse-
quently, potential treatment should target these underlying
conditions.
It is important to recognize that in human TBI, several
pathological derangements coincide; nevertheless, the classi-
ﬁcation of speciﬁc patterns of injury is useful as a conceptual
tool, a method of stratiﬁcation of patients in research studies
and a way of rationalizing treatments. We believe that
microdialysis may be utilized, concurrent with a wider panel
of multimodality parameters, to guide treatment as it opens
up a wider path of potentially treatable pathological condi-
tions than if ICP or other modalities are used in isolation.
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Pharmacokinetics of Neuroprotective Agents
One of the most important areas for pharmacological
studies in TBI is the development and efﬁcacy assessment of
neuroprotective substances, where the MD technique has
been a valuable addition in some studies.
Cyclosporin A, a calcineurin inhibitor, has shown good
neuroprotective effect in preclinical animal studies of TBI
(89–91), presumably by inhibiting the Ca2+-induced
mitochondrial membrane permeability transition leading to
less mitochondrial swelling and rupture of the outer
mitochondrial membrane (92). In a randomized controlled
trial treating severe TBI patients with cyclosporin A,
monitored with MD, brain energy metabolism improved
signiﬁcantly in the treated group (25).
In a study by Helmy et al., the authors treated severe TBI
patients with interleukin-1 receptor antagonist (IL1ra)
(Kineret®) in a double-blind randomized control trial (26).
The innate immune system is a key player in the detrimental
secondary injury cascades following TBI (93), and this
provides the rationale as to why it would be beneﬁcial to
target pro-inﬂammatory interleukin-1 activity. All patients
were monitored using MD, and not only were the authors
able to accurately study the pharmacokinetics in the brain
ECF of the subcutaneously administered drug, they also
noted the changes of downstream chemokines and cytokines
in the treated group vs placebo, extracted from the brain ECF
as well (26, 94). Similarly, another randomized control trial
analysing antipterin VAS203 (a nitric oxide synthase inhibi-
tor) in TBI noted increased metabolites of the drug in the
brain, extracted using MD, in the treatment group as
compared to those in placebo (95).
In a recently published clinical study, patients suffering
from severe spinal cord injury were monitored using MD
implanted intradurally at the site of injury (19). This allowed
the physicians to guide the spinal perfusion pressure and
spinal ECF glucose, as deviations from 90–100 mmHg and
4.5 mmol/L, respectively, resulted in an increase of the LPR
in the damaged area (19). The authors also noted that
dexamethasone penetration into the tissue increased with
increasing spinal perfusion pressure, prompting future trials
in spinal cord injury to better monitor the affected area.
In summary, MD offers the potential to monitor the
effect of delivered drugs into the injured CNS. Lessons from
previous studies show that pharmacokinetic monitoring is not
adequately used and by using MD monitoring, future trials
could be extensively improved.
Retrodialysis as a Route of Drug Administration
The design of the microdialysis allows not only substances to
be extracted and analysed but also substances to be delivered
through the membrane through a process referred to as
retrodialysis, when the concentration of a molecule is of higher
concentration within the microdialysis perfusate than the brain
ECF. Delivery of 13C-labelled substrates focally into brain via the
microdialysis catheter and simultaneous recovery of the 13C-
labelled metabolites in the emerging microdialysate has been
successfully performed in TBI patients (28, 96, 97). In preclinical
experiments, retrodialysis has recently been shown to successfully
deliver dexamethasone directly in both experimental TBI with
ameliorating effects (98) and to transgenic animals expressing
decreased microglia activity (99).
In their recently published study, Jalloh and co-workers
delivered 2,3-13C2 succinate through microdialysis catheters
directly into the brain parenchyma of patients suffering from
severe TBI (28), as succinate has been shown to act as energy
substrate in affected mitochondria (100). Jalloh et al. demon-
strated a decrease in LPR in patients with raised LPR at the
time, supporting the thesis that succinate can normalize
deranged energy metabolism and potentially ameliorate
mitochondrial dysfunction by bypassing complex I of the
mitochondrial membrane electron transport chain (ETC)
(28). Succinate is energetically important as it is both a
TCA cycle intermediate and a direct contact between the
TCA cycle and the mitochondrial ETC complex II (succinate
dehydrogenase (SDH)), on the mitochondrial inner mem-
brane. An important feature of the study by Jalloh et al. was
their use of double 13C-labell ing, which proved
unambiguously that the substrate molecules (2,3-13C2
succinate) crossed from the microdialysis perfusate into the
brain extracellular space, entered cells and were metabolised,
and the metabolites exported into the extracellular ﬂuid, and
recovered by the microdialysis catheter. The characteristic
NMR doublets arising from two adjacent 13C atoms prove
cellular uptake and mitochondrial metabolism of 2,3-13C2
succinate revealing downstream metabolites. Doublets are
clearly distinct from native endogenous molecules, because
Table II. Overview of the Suggested Pathophysiological Targets
Pathological target
(if LPR > 25)
ICP (mmHg) Auto-regulation
(PRx)
PbO2 (mmHg) Brain glucose
(mmol/L)
Treatment
Intracranial hypertension >20–25 X X X Increase sedation, hypertonic
saline, decompressive craniectomy etc.
Delivery failure <20–25 >0.3 X X Increase CPP
Diffusion barrier <20–25 <0.3 <15 X Increase FiO2
Neuroglycopenia <20–25 <0.3 >15 0.5–1.0 Increase systemic glucose levels
Mitochondrial dysfunction <20–25 <0.3 >15 >1.0 None available
Deﬁnitions of intracranial hypertension, delivery failure, diffusion barrier, hypoglaceamia and mitochondrial dysfunction. ‘X’ indicates that it
this modality does not discriminate for the target of interest. ‘Treatment’ represents tentative treatment strategies for the different pathological
targets
PRx pressure reactivity index, PbO2 brain tissue oxygen pressure, as measured with intracranial oxygen pressure device, ICP intracranial
pressure, CPP cerebral perfusion pressure, FiO2 fraction of inspired oxygen
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the probability of two endogenous 13C atoms being adjacent
to each other naturally is 0.01% (a 1 in 10,000 chance) and
indistinguishable from baseline ‘noise’ in the NMR spectra.
As SDH is exclusively mitochondrial, downstream
metabolites of 2,3-13C2 succinate must be derived from
pathways stemming from mitochondrial metabolism.
Not only does delivery byMDopen up a new administration
route for several promising neuroprotective agents for micro-
dosing in a research setting but it also allows the possibility to
assess efﬁcacy (bypassing the BBB) in the treated area.
CONCLUSIONS
Clinical MD has emerged as an important addition to
conventional intracranial monitoring of patients suffering
from severe TBI. While the technique is associated with
some caveats, new research further facilitates the usage and
assessment of clinical MD. New pharmacological trials
targeting the injured CNS will beneﬁt from better monitoring,
where the MD technique will be able to determine pharma-
cological concentration and dose-response effect in brain
ECF. Finally, the MD, together with other monitoring
modalities, may in the future help the clinician establish
treatable pathophysiological targets.
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